Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
papiliximab
- Development stage
- Unknown
- Lead developer
- Shaperon
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Papiliximab is a bispecific monoclonal antibody developed by Shaperon. It targets both CD47 and programmed death-ligand 1 (PDL1), functioning as an inhibitor of these immune checkpoint proteins. By blocking CD47 and PDL1, papiliximab is designed to enhance the immune system's ability to recognize and destroy cancer cells. The drug is being investigated primarily for the treatment of neoplasms (cancers) and has reached early Phase 1 clinical development[1][2]. It is described as a nanobody-based dual-target antibody[7].
- Other names
- PDL1-CD47 dual nanobodyPDL-1-CD47 dual nanobodyPDL 1-CD47 dual nanobodyanti-cancer PDL1-CD47 dual nanobody
02
Targets
CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on papiliximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on papiliximab.